Illumina News and Research

RSS

Comprehensive data analysis and interpretation offered to customers as a result of collaboration between ATLAS Biolabs and Ingenuity systems

ATLAS Biolabs and Ingenuity® Systems have signed a collaboration agreement that gives ATLAS Biolabs’ customers the option to analyse and interpret their study data using Ingenuity solutions.

19 Jun 2012

Illumina's new patent infringement suit targets Complete Genomics' cPal read technology

Illumina (NASDAQ:ILMN) announced today that the company has filed an additional patent infringement suit against Complete Genomics, Inc. Illumina is seeking all available remedies, including injunctive relief.

From Illumina, Inc. 18 Jun 2012

Illumina launches Nextera XT DNA Sample Preparation Kits

Illumina today introduced the Nextera XT DNA Sample Preparation Kit, the easiest way for researchers to prepare and sequence small genomes, PCR amplicons, and plasmids.

From Illumina, Inc. 1 Jun 2012

QCMG establishes Illumina technology as core sequencing platform

Illumina today announced that the Queensland Centre for Medical Genomics (QCMG), home of Australia's International Cancer Genomics Consortium program, has established Illumina technology as its core sequencing platform in an expanded facility.

30 May 2012

Helico reaches patent litigation settlement with Pacific Biosciences

Helicos BioSciences Corporation announced today that it has settled its patent infringement litigation against Pacific Biosciences, Inc.

15 May 2012

Scientists discover new type of dynamic change in human stem cells

A team led by scientists at The Scripps Research Institute and the University of California (UC) San Diego has discovered a new type of dynamic change in human stem cells.

4 May 2012

LifeCodexx completes PraenaTest clinical study on trisomy 21

LifeCodexx today announced the successful completion of the clinical validation study of its noninvasive test method for the detection of fetal trisomy 21 from maternal blood using Next Generation sequencing.

2 May 2012

ISS recommends Illumina shareholders to vote against Roche's nominees

Roche released the following statement in response to a report issued by Institutional Shareholder Services recommending that shareholders of Illumina, Inc. vote against the election of Roche's independent director nominees to Illumina's Board of Directors.

From Illumina, Inc. 7 Apr 2012

RainDance introduces new panel for cancer mutation screening

RainDance Technologies, Inc., the Digital Biology company, today announced the worldwide availability of its new panel for cancer mutation screening research using any next-generation sequencing (NGS) system.

2 Apr 2012

Roche announces increase in offer price for outstanding Illumina shares

Roche announced today that it has increased its offer price for all outstanding publicly-held shares of Illumina, Inc. to US$ 51.00 per share in cash.

From Illumina, Inc. 29 Mar 2012

CRG, Illumina partner for large-scale analysis of genetic variation and function

The Centre for Genomic Regulation (CRG) has recently signed a year-long collaboration agreement with Illumina, a leading developer and manufacturer of life sciences tools and integrated systems for large-scale analysis of genetic variation and function.

From Illumina, Inc. 28 Mar 2012

NCGR to host eighth annual NMBIST symposium on March 22-23, 2012

The National Center for Genome Resources (NCGR) announced today that it will host the eighth annual New Mexico Bioinformatics, Science and Technology (NMBIST) symposium on March 22-23, 2012.

7 Mar 2012

Illumina launches new highly multiplexed cancer panel

Illumina today introduced the TruSeq Amplicon - Cancer Panel, a highly multiplexed panel that will allow researchers to accurately sequence hundreds of the most relevant cancer loci, even in difficult samples such as formalin-fixed, paraffin embedded (FFPE) tumor samples.

From Illumina, Inc. 7 Mar 2012

Roche extends cash tender offer to acquire all shares of Illumina

Roche announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc., at a price of $44.50 per share, to 6:00 p.m., New York City time, on March 23, 2012.

From Illumina, Inc. 27 Feb 2012

Researchers sequence genome of Tasmanian devil contagious cancer

Researchers have sequenced the genome of a contagious cancer that is threatening the Tasmanian devil, the world's largest carnivorous marsupial, with extinction. Cataloguing the mutations present in the cancer has led to clues about where the cancer came from and how it became contagious.

17 Feb 2012

Illumina introduces Cancer Analysis Service from IGN

Illumina, Inc. today announced the launch of a Cancer Analysis Service from the Illumina Genome Network (IGN) that leverages the high accuracy of Illumina technologies to provide cancer researchers with easily interpretable tumor/normal sequencing data to quickly move their research forward.

From Illumina, Inc. 16 Feb 2012

Oxford Gene Technology develops optimised rare disease sequencing and analysis service

Oxford Gene Technology (OGT), a provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has extended its Genefficiency™ Sequencing Service to provide a dedicated service for investigating rare diseases. The specifically optimised version of the service will help investigators and clinicians identify causative mutations quickly, easily and without the need for in-house technical or bioinformatics expertise.

From Oxford Gene Technology 16 Feb 2012

Fluidigm announces availability of Access Array Barcode Library for Ion Torrent PGM

Fluidigm Corporation today announced the availability of the Access Array Barcode Library for the Ion Torrent Personal Genome Machine (PGM) sequencer. This barcode library allows multiplexing of up to 96 different samples in a single sequencing run.

13 Feb 2012

Roche proposes to acquire Illumina for $44.50 per share

Roche announced today that it is proposing to acquire all outstanding shares of Illumina, Inc. for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis.

From Roche Sequencing and Life Science 24 Jan 2012

DNA decoder – cheaper and faster

Life Technologies Corp. – a biotechnology company announced Tuesday that it has developed a machine to decode an individual's DNA in a day for just $1,000. The company said it was taking orders for the technology, which it expects to deliver in about a year. The Carlsbad, California, company said three major research institutions had already signed up for the $149,000 machine: the Baylor College of Medicine, the Yale School of Medicine and the Broad Institute of Cambridge, Massachusetts.

11 Jan 2012